{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:30Z","timestamp":1788869310299,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017521","name":"Esteve Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nrleng.2026.502040","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:44:03Z","timestamp":1784130243000},"page":"502040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spanish expert consensus statement on the use of inhaled levodopa for the treatment of fluctuations in Parkinson\u2019s disease"],"prefix":"10.1016","volume":"41","author":[{"given":"J.","family":"Pagonabarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bl\u00e1zquez-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Freire-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"L\u00f3pez-Manzanares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"L\u00f3pez-Ariztegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"S\u00e1nchez-Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.nrleng.2026.502040_bib0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.502040_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","article-title":"The spectrum of \u201coff\u201d in Parkinson\u2019s disease: what have we learned over 40 years?","volume":"51","author":"Chou","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.nrleng.2026.502040_bib0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00325481.2021.1936087","article-title":"On demand therapy for Parkinson\u2019s disease patients: Opportunities and choices","volume":"133","author":"Hauser","year":"2021","journal-title":"Postgrad Med"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502040_bib0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","article-title":"Early detection of wearing off in Parkinson disease: the DEEP study","volume":"20","author":"Stocchi","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502040_bib0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02074-2","article-title":"Real-world assessment of the impact of \u201cOFF\u201d episodes on health-related quality of life among patients with Parkinson\u2019s disease in the United States","volume":"21","author":"Thach","year":"2021","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.nrleng.2026.502040_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mdc3.12915","article-title":"The most bothersome aspects of off periods reported by individuals with Parkinson\u2019s disease","volume":"7","author":"Chahine","year":"2020","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502040_bib0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40120-022-00435-8","article-title":"Off-time treatment options for Parkinson\u2019s disease","volume":"12","author":"Fabbri","year":"2023","journal-title":"Neurol Ther"},{"issue":"10","key":"10.1016\/j.nrleng.2026.502040_bib0040","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/mds.28726","article-title":"On-demand therapy for OFF episodes in Parkinson\u2019s disease","volume":"36","author":"Olanow","year":"2021","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502040_bib0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JPD-230055","article-title":"Drugs to the rescue: comparison of on-demand therapies for off symptoms in Parkinson\u2019s disease","volume":"13","author":"Martinez-Nunez","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.nrleng.2026.502040_bib0050","series-title":"European medicines agency SmPC","year":"2019"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502040_bib0055","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.nrleng.2026.502040_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi technique in health sciences: a map","volume":"8","author":"Niederberger","year":"2020","journal-title":"Front Public Health"},{"issue":"7080","key":"10.1016\/j.nrleng.2026.502040_bib0065","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","article-title":"Statistics notes: Cronbach\u2019s alpha","volume":"314","author":"Bland","year":"1997","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502040_bib0070","article-title":"El coeficiente de correlacion de los rangos de spearman caracterizacion","volume":"8","author":"Ortega","year":"2009","journal-title":"Rev Haban de Cienc Med"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502040_bib0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502040_bib0080","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/mdc3.13690","article-title":"Expert consensus on the use of on-demand treatments for OFF Episodes in Parkinson\u2019s disease: a modified delphi panel","volume":"10","author":"Isaacson","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.nrleng.2026.502040_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1149615","article-title":"Impact of non-motor fluctuations on QOL in patients with Parkinson\u2019s disease","volume":"14","author":"Kakimoto","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502040_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.24227","article-title":"Non-Motor fluctuations in Parkinson\u2019s disease: underdiagnosed yet important","volume":"18","author":"Boura","year":"2025","journal-title":"J Mov Disord"},{"issue":"6","key":"10.1016\/j.nrleng.2026.502040_bib0095","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00702-023-02636-3","article-title":"Inhaled levodopa for threatening impending OFF episodes in managing Parkinson\u2019s disease","volume":"130","author":"Jost","year":"2023","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502040_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"18","author":"LeWitt","year":"2019","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.nrleng.2026.502040_bib0105","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/mds.26611","article-title":"A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease","volume":"31","author":"LeWitt","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.nrleng.2026.502040_bib0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.parkreldis.2020.10.029","article-title":"A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson\u2019s disease","volume":"81","author":"Farbman","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.nrleng.2026.502040_bib0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.parkreldis.2019.03.026","article-title":"Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson\u2019s disease","volume":"64","author":"Hauser","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.nrleng.2026.502040_bib0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol"},{"issue":"S01","key":"10.1016\/j.nrleng.2026.502040_bib0125","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33588\/rn.78S01.2024196","article-title":"Levodopa inhalada: de la evidencia a la experiencia","volume":"78","author":"Mart\u00ednez-Castrillo","year":"2024","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2026.502040_bib0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","article-title":"Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: a randomized 12-month pulmonary safety study","volume":"71","author":"Grosset","year":"2020","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:20:16Z","timestamp":1788866416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2173580826001173"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502040","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spanish expert consensus statement on the use of inhaled levodopa for the treatment of fluctuations in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502040"}}